Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 October 2024 | Story Anthony Mthembu | Photo Stephen Collett
Global Social Innovation Indaba
Panel discussion during the 2024 Global Social Innovation Indaba held at the University of the Free State, Bloemfontein Campus.

Insightful, thought-provoking and inspiring: These were some of the words used to describe the 2024 Global Social Innovation Indaba, which took place at the Centenary Complex on the University of the Free State’s (UFS’s) Bloemfontein Campus from 30 September to 2 October 2024.

The three-day conference was hosted by the global Social Innovation Exchange (SIX) in collaboration with the UFS, under the theme ‘People Powered Change’. The conference brought together leaders and innovators from South Africa and several other countries, including Louise Pulford, CEO of SIX; Markus Lux, Senior Vice-President at Robert Bosch Stiftung, and Desmond D’Sa from the South Durban Community Environment Alliance (SDCEA), among others.

In her opening address, Acting UFS Vice-Chancellor and Principal Prof Anthea Rhoda welcomed the guests and described the conference as an opportunity to “deliberate, debate, and dissect ideas around the all-important topic of harnessing people-powered change in order to build successful societies”.

Powering social change

As part of the conference guests engaged in a series of panel discussions and activities, and attended presentations on various topics.

D’Sa was one of the first speakers, delivering a keynote address titled ‘An activist guide to people-powered change’. He referred to moments throughout his career in which he has actively worked towards change in his community and beyond, and highlighted some of the work the SDCEA continues to do. Guests were also treated to a spoken word performance by Napo Masheane, Artistic Director at the Performing Arts Centre of the Free State (PACOFS).

Advocate Tembeka Ngcukaitobi touched on several points in his talk, such as what the law meant or means to indigenous people. He explored this by referring back to the colonialist era. Ngcukaitobi, who described law as the most ubiquitous and most stable concept that European settlers brought, indicated that it was brought in two faces: the face of justice, and the face of violence. Therefore, he said, “… the future of law that has been most enduring is the ability of the law to transform itself from violence to justice.”

Guests said they regarded the presentations and dialogues as insightful, and also highlighted their appreciation for being able to interact with the campus itself. This sentiment in large part stemmed from the attendees being split into smaller groups and taken to see different parts of the campus. They also got to see an exhibition exploring the role of art in social justice at the Department of Fine Arts.

Lessons from the conference

The last day featured a panel discussion titled ‘Challenging power dynamics and redefining global exchange’, which included an engagement session with the audience. Guests were able to reflect on the information they had acquired at the conference and challenged themselves to continue working towards change and innovation.

“What I learnt from these three days is that since we all want to do the right thing, we all know what the job that needs to be done is,” said Michael Ngigi, CEO of Thinkplace Africa. “As such, we need to be bold in going for that, and really push back on the status quo that is formed by the places we represent.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept